Pete, I understand your skepticism. Based on the information we as a group have uncovered it appears like management has been less then forthright. However Simes has constantly stated that they want to maximize shareholder value(he didn't say when and where)and for this reason those who remain should be well rewarded. If not, unlike previous lawsuits which were frivolous the one we as group will launch would have teeth.
Now, with everything that has transpired, I believe a buyout is in the works. The buyout would have to pass a shareholder vote. The share holders including institutional shareholders would know if the deal was a low ball offer. Such an offer would get rejected. Abbott and Biosante's Boards & Management teams are not stupid. The offer would have to be fair in order to pass a vote and avoid another big pharma company from stepping in which would end up costing Abbott much more in the long run if they wanted to attain their goal of being lead in expanding the use of testosterone.
A number of companies were offered $2.5 to $3.5 billion this year with much less revenue potential then what we have uncovered. The other deals and their revenue potential will be the gauge for a fair deal.
Love it or hate it we have on our side Tang and he has sued companies in the past who tried to sell for less then what he believed the company was worth.
Use the Ardea Bioscience's sale to Astrazeneca for $1.26 Billion as a guide as to what Tang would believe the company is worth.(Tang was a Director)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.